Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cathy Kelly

Senior Writer

Washington, DC

Cathy has covered prescription drug reimbursement issues for nearly 20 years, starting with the implementation of the Medicare Part D program. She has written extensively about developments in all the major US insurance sectors -- Medicare (Parts D and B), Medicaid and the employer-sponsored market. She has closely followed the increasing influence of pharmacy benefit managers and their use of formulary negotiations and rebates to control pricing. Cathy also has covered the implementation of frameworks for assessing drug value by medical professional organizations and the Institute for Clinical and Economic Review and is watching with interest as the government develops new policies aimed at lowering drug pricing.

For more than three decades, she has worked as a health care reporter and editor while raising three daughters. Cathy lives in Bethesda, MD with her husband Sean.

Latest From Cathy Kelly

Medicare Part B Premium Reduction In 2023 Has Reserves Built In If Lecanemab Launches

But premiums in future years made need to keep pace with accelerating Medicare spending on Alzheimer’s drugs.

Reimbursement Medicare

Lecanemab And Medicare: Could Better FDA/CMS Communication Improve Coverage Chances?

Eisai/Biogen’s promising Phase III data fueling the companies’ hopes that Medicare will relax coverage restrictions for their Alzheimer’s treatment candidate. If the sponsors fail to change the NCD, lecanemab will need to rely on a registry for reimbursement after full approval.

Reimbursement Medicare

Medicare Price ‘Negotiation’ Process Could Enable National Value Framework – CMS’ Blum

Centers for Medicare and Medicaid Services chief operating officer Jonathan Blum discusses implementation of an unprecedented new price setting program and how it might impact value-based pricing more broadly in a recent interview with Health Affairs.

Pricing Debate Reimbursement

Arnold Ventures: How A Philanthropy Helped Tip The Scales In US Drug Pricing Debate

A review of grants by the organization to a range of recipients engaged in work on lowering drug prices. 

Pricing Debate Lobbying

Accelerated Approval Price Trends Show Sponsors Can ‘Lose But Not Win’ From Confirmatory Trials

Study drills down into the lack of economic incentives for conducting confirmatory studies to inform policies that could remedy to the situation.

Pricing Debate Review Pathway

Medicare Part D Price Inflation Rebates Won’t Mean As Much In Inflationary Times

Fewer rebate penalties than lawmakers expected may be assessed in the coming year because of the current high rate of general inflation.

Pricing Strategies Reimbursement
See All